

# CODEBASE VENTURES INC.

06:30 10 Jul 2020

## Codebase Ventures helps early-stage technology and cannabis companies reach full potential

- Venture capital company investing in early-stage technology and cannabis companies
- Has invested in companies such as blockchain company Arcology and ICO Ranker
- Subsidiary Code Cannabis Investments focused on the expanding CBD market in North America and Europe

### What Codebase Ventures does:

Codebase Ventures Inc (CSE:CODE) (OTCMKTS:BKLLF) is a tech-centric investment firm. The venture capital company invests in early-stage technology and cannabis companies and is made up of a team of financial and technology experts.

The company aims to take stakes in fledgling companies with a focus on investing in companies with "outstanding talent, teams and technology," according to the firm's website. With its headquarters in Brooklyn, Codebase's team members are based globally from Belgrade to Vancouver.

Codebase has a number of companies within its portfolio including stakes in the blockchain company Arcology, as well as investments in ICO Ranker, the standard for reviews and analysis of token sales, and Blockchain Ranker, a business-to-business directory of blockchain software, service providers and platforms.

Arcology, in which it owns a 30% stake, runs a hierarchical blockchain that uses proprietary algorithms and artificial intelligence to eliminate inefficiencies that hinder rival blockchain platforms. ICO Ranker is a collaborative platform for the rating of ICOs and blockchain projects.

The company recently started targeting early-stage assets and startups in the emerging and promising cannabis sector by launching its newest subsidiary, Code Cannabis Investments. For now, the company is focused on the expanding market for CBD products in North America and Europe.

London-based World High Life PLC is the crown jewel of Code Cannabis's portfolio. World High Life is focused on backing or acquiring companies operating in the CBD wellness and medicinal cannabis industry and its wholly-owned subsidiary, Love Hemp is a leading CBD supplier in the United Kingdom.

### How is it doing:


Codebase has been actively pursuing pharmaceutical opportunities that could have a positive impact on the current global coronavirus pandemic.

In April, the firm acquired a 49% interest in Glanis Pharmaceuticals Inc, which recently filed for a US provisional patent for the transdermal delivery and oral mucosal delivery of hydroxychloroquine. Five out of seven completed clinical trials of the drug have shown favorable outcomes for coronavirus patients, although the company said more data is

**Price:** 0.155

**Market Cap:** \$7.8 m

#### 1 Year Share Price Graph



#### Share Information

**Code:** CODE

**Listing:** CSE

**52 week High Low**  
0.35 0.04

**Sector:** Financial Services

**Website:** [www.codebase.ventures](http://www.codebase.ventures)

#### Company Synopsis:

*Codebase Ventures Inc. is a small, hands-on team of financial and technology experts who invest early in great ideas. We operate from the understanding that technology is always evolving, bringing early opportunities for strategic investments that can deliver the exponential returns to our shareholders.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

necessary.

Meanwhile, investee company Arcology is advancing its presence among dAPP (decentralized application) developers by launching a project on GitHub, the world's largest source code sharing platform. An intelligent client-end simulator called Ammolite can simulate hundreds of thousands of dAPPs users on a network simultaneously.

In May, Codebase investee Trad3r launched a reimagined mobile game app and social media platform designed for users to trade thousands of different celebrities, sports teams, stocks and friends. Also in May, investee and psychedelics company Red Light Holland (CSE:TRIP) debuted its shares on the Canadian Securities Exchange.

But it's World High Life that has been in the news most recently. Sales of its Love Hemp brand increased by nearly 107% during the month of May compared to January 2020 levels. Love Hemp said its team has been "highly responsive" to customer needs throughout the coronavirus (COVID-19) pandemic, helping to increase awareness and the brand's capacity online to fuel sales.

### **Inflection points:**

- Explore opportunities in the UK and European CBD and medicinal-cannabis markets
- Growing sales of Love Hemp, LH Botanicals and other World High Life products
- Glanis Pharmaceuticals receiving patents for transdermal delivery and oral mucosal delivery of chloroquine and hydroxychloroquine

Increasing portfolio of companies through further investments

### **What the boss says:**

Commenting on World High Life's success amidst the current coronavirus pandemic, Codebase CEO George Tsafalas told shareholders: "Even under challenging global circumstances World High Life's Love Hemp subsidiary continues to expand its business as a leader in the UK, and building market share, which bodes well for its future growth, and to the benefit of our shareholders as a result of Codebase's early-stage investment."

Contact Angela at [angela@proactiveinvestors.com](mailto:angela@proactiveinvestors.com)

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of CODEBASE VENTURES INC. named herein, including the promotion by the Company of CODEBASE VENTURES INC. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).